title: Loss of imprinting of IGF2 and H19, loss of heterozygosity of IGF2R and CTCF, and Helicobacter pylori infection in laryngeal squamous cell carcinoma.
abstract: Imprinting analyses of IGF2 and H19, loss of heterozygosity (LOH) analyses of IGF2R and CTCF and Helicobacter pylori detection, were performed on 35 human laryngeal squamous cell carcinomas (LSCC). Forty-six percent of the tumors were heterozygous for IGF2, and 54% were informative for the H19. Biallelic expression of IGF2 was observed in 33% (5 out of 15) of the tumors and in 27% (4 out of 15) of adjacent non-tumorous laryngeal tissues. H19 loss of imprinting (LOI) was observed in 24% (4 out of 17) of the tumors. For IGF2R and CTCF, 71% (25 out of 35) and 50% (17/34), respectively, of the samples were heterozygous, and LOH was detected in 12% (3 out of 25) and 6% (1 out of 17), respectively, of the tumors. H. pylori was found in 26% (9/35) of these tumors. Among them, four were informative for the imprinting analysis. The presence of H. pylori had no effect on IGF2/H19 imprinting. Only the H. pylori detection was further broadened with an additional 47 laryngeal tumors, resulting in a total final positivity of close to 16% (13 out of 82). This study represents the largest comprehensive IGF2/H19 imprinting study done to date on well-defined samples of human laryngeal carcinomas and corresponding non-tumorous tissue. For the first time, the analyses of IGF2/H19 imprinting have been broadened with LOH analyses of IGF2R and CTCF, with both of these genes acting as modulators of IGF2 and H19 activity. Although there were indications that H. pylori may be present in LSCC, we are the first to show its presence in LSCC by two direct techniques: Giemsa staining and nested-PCR.
authors.affiliation: Laboratory of Molecular Pathology, Division of Molecular Medicine, Rudjer Boskovic Institute, Zagreb, Croatia. igrbesa@irb.hr
authors.forename: Ivana
authors.initials: I
authors.lastname: Grbesa
authors.forename: Marino
authors.initials: M
authors.lastname: Marinkovic
authors.forename: Mirko
authors.initials: M
authors.lastname: Ivkic
authors.forename: Bozo
authors.initials: B
authors.lastname: Kruslin
authors.forename: Renata
authors.initials: R
authors.lastname: Novak-Kujundzic
authors.forename: Boris
authors.initials: B
authors.lastname: Pegan
authors.forename: Ozren
authors.initials: O
authors.lastname: Bogdanovic
authors.forename: Vladimir
authors.initials: V
authors.lastname: Bedekovic
authors.forename: Koraljka
authors.initials: K
authors.lastname: Gall-Troselj
mesh_terms: D000076246:CCCTC-Binding Factor; D002294:Carcinoma, Squamous Cell / Q000235:genetics / Q000382:microbiology / Q000473:pathology; D004268:DNA-Binding Proteins / Q000235:genetics* / Q000378:metabolism; D018392:Genomic Imprinting; D016481:Helicobacter Infections; D016480:Helicobacter pylori / Q000378:metabolism / Q000472:pathogenicity; D006801:Humans; D007335:Insulin-Like Growth Factor II / Q000235:genetics* / Q000378:metabolism; D007822:Laryngeal Neoplasms / Q000235:genetics / Q000382:microbiology / Q000473:pathology; D019656:Loss of Heterozygosity; D062085:RNA, Long Noncoding; D022661:RNA, Untranslated / Q000235:genetics* / Q000378:metabolism; D017527:Receptor, IGF Type 2 / Q000235:genetics* / Q000378:metabolism; D012097:Repressor Proteins / Q000235:genetics* / Q000378:metabolism
chemical_list: D000076246:CCCTC-Binding Factor; C000619697:CTCF protein, human; D004268:DNA-Binding Proteins; C094335:H19 long non-coding RNA; D062085:RNA, Long Noncoding; D022661:RNA, Untranslated; D017527:Receptor, IGF Type 2; D012097:Repressor Proteins; D007335:Insulin-Like Growth Factor II